ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer

The combination of BEBT-209 with gemcitabine and carboplatin showed promising efficacy and a tolerable safety profile in metastatic triple-negative breast cancer (TNBC). Read More ›

Wrap-Up

NeoSTAR Arm A2: Evaluating Sacituzumab Govitecan and Pembrolizumab as Neoadjuvant Therapy for Early-Stage TNBC

Sacituzumab govitecan and pembrolizumab combination therapy showed promising clinical benefit in early-stage triple-negative breast cancer (TNBC). Read More ›

Wrap-Up

Efficacy and Safety of Camrelizumab, Apatinib, and Chemotherapy as Neoadjuvant Therapy for Stage II-III TNBC

ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer

The combination of camrelizumab, apatinib, and chemotherapy shows favorable outcomes in the neoadjuvant setting for stage II-III triple-negative breast cancer (TNBC), particularly in patients with programmed death-ligand 1 positivity. Read More ›

Wrap-Up

Phase 3 Trial of Benmelstobart Plus Anlotinib Versus Nab-Paclitaxel in First-Line Treatment of Recurrent or Metastatic TNBC

ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer

The combination of benmelstobart and anlotinib showed a numerical, though not a statistically significant improvement in progression-free survival and overall survival over nab-paclitaxel in recurrent or metastatic triple-negative breast cancer (TNBC). Read More ›

Wrap-Up

Phase 3 ASCENT-04/KEYNOTE-D19 Study: Sacituzumab Govitecan Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab in First-Line, PD-L1–Positive, Advanced TNBC

ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer

The ASCENT-04/KEYNOTE-D19 trial highlights sacituzumab govitecan plus pembrolizumab as a promising first-line therapy for patients with programmed death-ligand 1 (PD-L1)-positive, advanced triple-negative breast cancer (TNBC). Read More ›

Breast Cancer Coverage Brought to You By

ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer

Sponsored by